Bristol Myers Squibb account map & org chart

Eleven executives sit on the leadership team with Board Chair and CEO Chris Boerner¹. Robert Plenge runs Research as Chief Research Officer, and Cristian Massacesi is Chief Medical Officer and Head of Development — so discovery and clinical development sit under two different executives. Adam Lenkowsky runs the worldwide commercial and medical organizations as Chief Commercialization Officer. Karin Shanahan runs supply chain and operations. Two businesses have their own president on the leadership team: Lynelle Hoch for the Cell Therapy Organization and Ben Hickey for RayzeBio, its standalone radiopharmaceutical business.

• We found 375 Bristol Myers Squibb teams hiring in the past four quarters, and 7,444 leaders at Associate Director level or above. All of it from public sources.
• Neuroscience hires the most: 111 open roles in the past four quarters, followed by Cell Therapy (100) and Oncology (85). Customer Insights & Engagement is growing fastest, from 3 roles to 9. Observed postings across the company fell to 0.4 times the prior window, so read every unit's multiple against that baseline.
• Most of the hiring is in the United States (4,817 location listings), then India (447) and Switzerland (95). Princeton is the busiest city, with 931, and Hyderabad is second with 424.
• Bristol Myers Squibb reports its business as a single operating segment: innovative medicines, discovered, developed, made and sold worldwide³·⁴.

The 30 most active units by open roles in the trailing four quarters, of 375 units with any hiring activity in the window (drawn from 5,334 verbatim-extracted unit-name candidates). Rows are centers of activity, not an org chart — several (therapeutic areas especially) sit inside larger divisions rather than beside them. = corroborated by 2+ independent sources.

Reading the momentum column

Momentum is the unit's own posting count, last four quarters vs the four before: ▲ 2.0× = twice as many postings. The arrow marks units moving well beyond (or against) the company-wide trend — and because observed BMS postings fell to 0.4× window-over-window, a unit can carry an up-arrow with a multiple below 1.0: it is gaining share of a shrinking observed total. Too little history shows "—" rather than a noisy number.

How to use this page. A unit gaining hiring share is standing up capacity — the best moment to engage is while teams and tooling are still being chosen. A unit losing share may be post-reorg, outsourcing, or completing a build-out; treat the flag as a prompt to ask, not a conclusion.

Posting locations for the trailing four quarters of hiring, aggregated across all mapped units. Counts are location listings — a posting advertised in several locations counts once per location, so totals exceed distinct postings. Use this to route territory and plan on-site coverage.

Named Associate Director+ leadership for the busiest centers of work. Every row is flagged for currency: verified = confirmed as current during this snapshot's verification pass (a web check, an active-position signal, or the company's own page); verify = sourced but not recently re-confirmed — check before outreach. In this public edition, a lock marks a leader named in the full map.

Centers whose own staff lead-author peer-reviewed papers, from author affiliations in the scientific literature (2023–2026). Papers attach to a center only when the paper's affiliation names it exactly, so counts are lead-authored published evidence, not a census; 54 mapped centers carry publications in total. Several of these centers barely hire publicly — the literature is the only channel that surfaces them.

The full map lists each center's papers, the diseases, targets, techniques, and instruments they name, and which leaders close the author list on the center's own work — independent corroboration that they run the group.

Bristol Myers Squibb's stated leadership structure, drawn as reported: the leadership team as the company lists it¹, with each executive's organization taken from their own profile page, the 10-K, or the careers site. Every numbered superscript links to its source. A blue count on a card marks an organization whose internal structure is mapped in the following sections: official sub-organizations as boxes, observed teams as ◦ chips. BMS reports a single operating segment³, so unlike some peers there are no segment badges to draw.

Reading order for the next two sections: Research first — the largest mapped organization — then the commercial organization, RayzeBio, and supply chain. Development (Cristian Massacesi) is drawn as one box: BMS publishes its scope but not its internal structure, and the development-side centers appear in the leadership tables above.

Boxes are official organizations as BMS describes them on its careers site¹⁶ — recruiting copy rather than a governance source, so treat the boxes as the company's own description of how Research is arranged, not a reporting chart. Muted chips marked ◦ are teams observed in BMS's hiring activity and scientific literature (the mined corpus behind the rest of this map), attached beneath the official unit they sit in; a gray "4 roles·4q" means 4 open roles observed for that team in the trailing four quarters.

The commercialization organization, the RayzeBio subsidiary, and supply chain, mapped the same way — official cited boxes, observed ◦ chips — with the way BMS groups its remaining functions below.

How is Bristol Myers Squibb organized in 2026?

Eleven executives sit on the leadership team with Board Chair and CEO Chris Boerner¹. Research (Robert Plenge) and Development (Cristian Massacesi, who is also Chief Medical Officer) are separate organizations. Adam Lenkowsky runs the worldwide commercial and medical organizations, and Karin Shanahan runs supply chain and operations. Two businesses have their own president: the Cell Therapy Organization (Lynelle Hoch) and RayzeBio (Ben Hickey). The corporate functions are finance (David Elkins), legal and policy (Cari Gallman), people (Amanda Poole), digital and technology (Greg Meyers), and corporate affairs (Wendy Short Bartie). BMS reports its business as a single operating segment.

Who leads Bristol Myers Squibb's research and development?

Two people. Robert Plenge, Executive Vice President and Chief Research Officer, leads Research: the six Thematic Research Centers, drug discovery, translational medicine, and informatics. Cristian Massacesi, Executive Vice President, Chief Medical Officer and Head of Development, leads early- and late-stage product development across all therapeutic areas.

Which Bristol Myers Squibb units are hiring the fastest in 2026?

Compared with the four quarters before, Customer Insights & Engagement grew 3 times (3 roles to 9), Clinical Engineering & Operations and QC Sample Management 2.7 times (3 to 8 each), Cell Therapy Manufacturing 2 times (8 to 16), and QC Analytical 1.5 times (10 to 15). Observed postings across the company fell to 0.4 times the prior window, so these units are gaining share of a smaller total. By volume, Neuroscience posts the most roles (111), then Cell Therapy (100) and Oncology (85).

Where is Bristol Myers Squibb hiring?

Mostly in the United States, which accounts for 4,817 location listings. The busiest cities are Princeton (931), Minneapolis (203), New Brunswick (197), and Summit (162). Outside the U.S., India has the most (447 listings, almost all in Hyderabad), then Switzerland (95, mainly Boudry) and Ireland (88).

What is an account map?

A view of a large company one level below the org chart: the named teams and departments where budgets get spent and vendors get chosen. We rank them by hiring activity and show who leads them, using only what the company makes public. That means job postings, scientific papers, leadership pages, and SEC filings. This page is the redacted version; the full PDF names every leader we identified.